Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity... by Sean Wharton, Julio Rosenstock, Manige Konige, Yanzhu Lin, Kevin Duffin, Jonathan Wilson, Hiya Banerjee, Valentina Pirro, Christof Kazda, Kieren Mather

Get full text